Last reviewed · How we verify

Adefovir dipivoxil or Entecavir

Ying-Jie Ji · Phase 2 active Small molecule Quality 3/100

Adefovir dipivoxil or Entecavir is a Small molecule drug developed by Ying-Jie Ji. It is currently in Phase 2 development. Also known as: ADV, Hepsera,, ETV, Baraclude.

At a glance

Generic nameAdefovir dipivoxil or Entecavir
Also known asADV, Hepsera,, ETV, Baraclude
SponsorYing-Jie Ji
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adefovir dipivoxil or Entecavir

What is Adefovir dipivoxil or Entecavir?

Adefovir dipivoxil or Entecavir is a Small molecule drug developed by Ying-Jie Ji.

Who makes Adefovir dipivoxil or Entecavir?

Adefovir dipivoxil or Entecavir is developed by Ying-Jie Ji (see full Ying-Jie Ji pipeline at /company/ying-jie-ji).

Is Adefovir dipivoxil or Entecavir also known as anything else?

Adefovir dipivoxil or Entecavir is also known as ADV, Hepsera,, ETV, Baraclude.

What development phase is Adefovir dipivoxil or Entecavir in?

Adefovir dipivoxil or Entecavir is in Phase 2.

Related